Timothy Perren

14.4k citations

151 papers · 6.6k indexed · 1 hit paper · h-index 42

Impact in

Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment
Oncology top 0.5%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy

Papers in

Reproductive Medicine 71
- Ovarian cancer diagnosis and treatment 69
Oncology 61
- Cancer Treatment and Pharmacology 21
- HER2/EGFR in Cancer Research 12

Co-authors: Peter J. Selby Gordon C. Jayson P Selby Rosamonde E. Banks Sean Kehoe Matthew Nankivell Jane Hook Mahesh Parmar
Journals: British Journal of Cancer (23 papers)Journal of Clinical Oncology (23 papers)Annals of Oncology (17 papers)European Journal of Cancer (7 papers)Cancer Chemotherapy and Pharmacology (5 papers)
Partner nations: United Kingdom Canada Australia

In The Last Decade

Timothy Perren

148 papers receiving 6.4k citations

Hit Papers

align trajectories log scale

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial 2015 · 945 citations

Peers

Countries citing papers authored by Timothy Perren

Since Specialization

Citations

This map shows the geographic impact of Timothy Perren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Perren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Perren more than expected).

Fields of papers citing papers by Timothy Perren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Perren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Perren. The network helps show where Timothy Perren may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Timothy Perren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Timothy Perren Line = papers co-authored together Timothy Perren links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study Breast Cancer Research and Treatment ·Mark Axelrod, Stefan N. Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Karen McAdam, Peter Schmid, Simon Waters, Christopher Poole, Chris Twelves, Timothy Perren, John M.S. Bartlett, Tammy Piper, T. Hosni, Michelle Welsh, Robert Hill, Lisa Hopcroft, Peter Barrett‐Lee, David Cameron	2023	8
2	815MO The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients Annals of Oncology ·Benoît You, Manoj Bhutte, Michel Tod, Gabe S. Sonke, Roy F.P.M. Kruitwagen, Andreas du Bois, Frédèric Selle, Timothy Perren, Jacobus Pfisterer, Florence Joly, Adrian Cook, Nor Fatihah, K. Wollschlaeger, Alain Lortholary, Lindy Dierks, Alexandra Léary, Gilles Freyer, Maaike A. van der Aa, Olivier Colomban	2020	3
3	Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials Obstetrical & Gynecological Survey ·Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B. Kristensen, Mahesh Parmar, Tom Ehlen, Gordon C. Jayson, Nick Johnson, Karolina Åström, René H.M. Verheijen, W. Glenn McCluggage, Timothy Perren, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Gavin Stuart, N.S. Reed, Sean Kehoe	2019	30
4	Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study International Journal of Gynecological Cancer ·Marcia Hall, Gianfilippo Bertelli, Rebecca B. Richardson, Clare Green, Stephen Chan, Jacob Richardson, Jurjees Hasan, Rachel Jones, 祐次田原, Timothy Perren	2019	19
5	ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis Annals of Oncology ·Rahmath Fida, Iain A. McNeish, Andrew Dean, David Gallardo, T. A. Carter, Dearbhaile M. O’Donnell, Jane Hook, C. Coyle, Sarah P. Blagden, James D. Brenton, Raj Naik, Timothy Perren, Sudha Sundar, Adrian Cook, Elizabeth C James, Ann Marie Swart, Sally Stenning, Richard Kaplan, Jonathan A. Ledermann	2017	38
6	ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer UCL Discovery (University College London) ·Y. Freitas Silva, Timothy Perren, Xiaobin Ji, W. Schroeder, Éric Pujade-Lauraine, Hanne Havsteen, Philip Beale, مريم عبد العظيم حسين, Arielle Reindeau, M.K.B. Parmar	2013	21
7	Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial UCL Discovery (University College London) ·JA Ledermann, Timothy Perren, Jing Pin Zou, Andrew Embleton-Thirsk, G.J.S. Rustin, Gordon C. Jayson, S.B. Kaye, Xiaobin Ji, Michelle Vaughan, Hal W. Hirte	2013	75
8	ICON7: FINAL OVERALL SURVIVAL RESULTS IN THE GCIG PHASE III RANDOMISED TRIAL OF BEVACIZUMAB IN NEWLY DIAGNOSED OVARIAN CANCER UCL Discovery (University College London) ·Éric Pujade-Lauraine, Y. Freitas Silva, Timothy Perren, Xiaobin Ji, Sven� Mahner, Lluís Serra‐Domínguez, Susanne Malander, M. Plante, Philip Beale, Andrés Poveda, Rachel M. Kaplan, Arielle Reindeau, M.K.B. Parmar	2013	6
9	Targeted anti-vascular therapies for ovarian cancer: current evidence British Journal of Cancer ·Marcia Hall, Charlie Gourley, Iain A. McNeish, Jonathan A. Ledermann, Martin Gore, Gordon C. Jayson, Timothy Perren, Gordon Rustin, Stan B. Kaye	2013	59
10	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer Journal of Clinical Oncology ·Jonathan A. Ledermann, Allan Hackshaw, K. Frank-Raue, Gordon C. Jayson, Hani Gabra, Iain A. McNeish, Helena Earl, Timothy Perren, Martin Gore, Mojca Persic, Malcolm Adams, Lindsay E. James, Graham Temple, Michael Merger, Gordon Rustin	2011	164
11	A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer Annals of Oncology ·Gordon Rustin, Nicholas Reed, Gordon C. Jayson, Jonathan A. Ledermann, Malcolm Adams, Timothy Perren, Christopher Poole, M. Lind, Mojca Persic, Sharadah Essapen, Martin Gore, Hilary Calvert, J G Bellows, (unknown), Marius Giurescu, Stuart Kaye	2011	23
12	ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC) UCL Discovery (University College London) ·Timothy Perren, Xiaobin Ji, Jacobus Pfisterer, JA Ledermann, Alain Lortholary, Gunnar B. Kristensen, Mark Carey, Philip Beale, Andrés Cervantes, Amit M. Oza	2010	34
13	The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma Archives of Gynecology and Obstetrics ·Naveen Vasudev, 段惠萍, David A. Cairns, Geoff Hall, David Jackson, 弘志角替, VLADIM�R �IMANSK�, Richard Hutson, David Nugent, Timothy Perren	2010	27
14	p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial Annals of Oncology ·Angelo Di Leo, Minna Tanner, Christine Desmedt, Marianne Paesmans, Fátima Cardoso, Virginie Durbecq, Stephen Chan, Timothy Perren, Matti Aapro, Christos Sotiriou, M. Piccart, Denis Larsimont, Jorma Isola	2007	49
15	Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation British Journal of Cancer ·Judith Dent, Geoff Hall, Nafisa Wilkinson, Timothy Perren, I Richmond, Alexander F. Markham, H. C. Murphy, Sandra Bell	2003	26
16	Routine Chest Radiography Following Imaging‐Guided Placement of Tunneled Central Lines: A Waste of Time, Money, and Radiation Nutrition in Clinical Practice ·David Kessel, Edward Taylor, Iain Robertson, Jai V. Patel, Chun‐Nan Hsu, Timothy Perren	2002	4
17	Bruchverhalten von AO-3,5-mm-Kortikalis-Titanschrauben (Synthes®-Schrauben) in Kombination mit LC-DCP-Platten Zeitschrift für Orthopädie und ihre Grenzgebiete ·Timothy Perren, Marius von Knoch, P Matter	2001	2
18	A phase II study of recombinant interferon-β (r-hIFN-β 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma British Journal of Cancer ·Carlos Augusto Martínez Hernández, Timothy Perren, C. Bradley, John Primrose, R Mahmodi, W. B. Millard, A.M. Nagaraja, P Selby	1997	5
19	Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience British Journal of Cancer ·M. Gore, Vincent Lévy, Gordon Rustin, Timothy Perren, A H Calvert, Helena Earl, JM Thompson	1995	45
20	The endodermal sinus tumour and clear cell ovarian cancer Annals of Oncology ·E O’Brien, Timothy Perren, Sylvia Tan, Cyril Fisher, E. Wiltshaw	1994	2

About Timothy Perren

Timothy Perren is a scholar working on Reproductive Medicine, Oncology, Cancer Research, Pathology and Forensic Medicine and Obstetrics and Gynecology, having authored 151 papers that have together received 6.6k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (69 papers), Intraperitoneal and Appendiceal Malignancies (28 papers), Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (20 papers), Renal cell carcinoma treatment (14 papers), HER2/EGFR in Cancer Research (12 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Reproductive Medicine (2.2k citations), Oncology (3.0k citations), Obstetrics and Gynecology (855 citations), Cancer Research (873 citations) and Pathology and Forensic Medicine (806 citations). Timothy Perren has collaborated with scholars based in United Kingdom, Canada and Australia. Frequent co-authors include Peter J. Selby, Gordon C. Jayson, P Selby, Rosamonde E. Banks, Sean Kehoe, Matthew Nankivell, Jane Hook, Mahesh Parmar, David Luesley and Sharadah Essapen. Their work appears in journals such as British Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact